GENEVA, March 19 (Reuters) - The World Health Organization's
vaccine safety panel said on Friday that data from AstraZeneca's
COVID-19 shot do not point to any overall increase in
clotting conditions but it would continue to monitor its
effects.
"The AstraZeneca COVID-19 vaccine (including Covishield)
continues to have a positive benefit-risk profile, with
tremendous potential to prevent infections and reduce deaths
across the world," the WHO's global advisory committee on
vaccine safety said in a statement issued after its independent
experts met on Tuesday and on Thursday to review data.
(Reporting by Michael Shields in Zurich; editing by Stephanie
Nebehay)